^
    3d
    Renal cell carcinoma with biphasic morphology: A cohort showing similar morphology but distinct clinicopathological and molecular features. (PubMed, Pathol Res Pract)
    In TFE3-rearranged RCC, the fusion gene might influence morphology or PD-L1 expression, thereby be likely to affect the efficacy of immunotherapy. Assessment of a combination of histological morphology, immunophenotype, and genetic alterations can facilitate precise pathological diagnosis of RCC, supporting personalized targeted therapy and prognosis assessment.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • GPNMB (Glycoprotein Nmb) • CTSK (Cathepsin K) • TFEB (Transcription Factor EB 2)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    PD-L1 IHC 22C3 pharmDx
    4d
    A comprehensive analysis of the correlation between plasma cytokines/chemokines and tumor immune microenvironment signature influences the response of checkpoint inhibitors in advanced non-small-cell lung cancer. (PubMed, Clin Transl Immunology)
    These findings underscore the crucial role of synergistic treatment in augmenting the efficacy of ICIs. The crosstalk between neutrophils and B cells in the orchestration of ICIs therapy for NSCLC was further elucidated through the roles of HSD17B11, SORL1, and TREM1.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • FOXP3 (Forkhead Box P3) • SORL1 (Sortilin Related Receptor 1)
    |
    PD-L1 IHC 22C3 pharmDx
    7d
    Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trials. (PubMed, Lung Cancer)
    Durvalumab-containing combination therapy showed promising efficacy in patients with R/M PSC, irrespective of PD-L1 expression. A lower CD4+/CD8+ ratio may be associated with favorable disease control.
    P2 data • Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Imfinzi (durvalumab)
    7d
    TROPION-Breast05: A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P3, N=625, Recruiting, AstraZeneca | Trial completion date: Apr 2029 --> Sep 2030 | Trial primary completion date: Oct 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • Datroway (datopotamab deruxtecan-dlnk)
    7d
    Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) (clinicaltrials.gov)
    P3, N=1170, Active, not recruiting, Daiichi Sankyo | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Datroway (datopotamab deruxtecan-dlnk)
    16d
    PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma. (PubMed, Oral Surg Oral Med Oral Pathol Oral Radiol)
    In R/M HNSCC, integrating IP with PD-L1 expression may enhance prediction of ICI outcomes.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    PD-L1 IHC 22C3 pharmDx • Lunit SCOPE IO
    18d
    BTCRC-LUN19-396: Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, Nasser Hanna | Recruiting --> Active, not recruiting
    Enrollment closed • Circulating tumor DNA
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • Tecentriq (atezolizumab) • docetaxel • pemetrexed
    21d
    Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Washington University School of Medicine | Trial completion date: Sep 2026 --> Jan 2027 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Opdivo (nivolumab) • albumin-bound paclitaxel
    1m
    Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • Jiataile (sacituzumab tirumotecan)
    1m
    KEYNOTE A99: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (clinicaltrials.gov)
    P1/2, N=296, Active, not recruiting, Inhibrx Biosciences, Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
    |
    EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • ordastobart (INBRX-106)
    1m
    ALPACA: A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Bavencio (avelumab)
    1m
    Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial (clinicaltrials.gov)
    P1/2, N=63, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • etoposide IV